PRAME-targeted ImmTAC® efficiently redirected T cells to kill tumour cells, with activity enhanced by anti-PD-1 therapy, highlighting its potential across multiple cancer types. 📖 vist.ly/595zb #Immunotherapy #Oncology #CancerResearch

🔬 MAGE-A4-specific TCR-NK cells showed potent preclinical activity against solid tumors, combining targeted and innate tumor killing in a promising off-the-shelf cell therapy. 🔗 vist.ly/593g8

M2 macrophages may help protect against asthma by promoting IL-10⁺ regulatory B cells. In a mouse model, macrophage depletion worsened asthma symptoms, while findings suggest M2 macrophages support IL-10⁺ B-cell activity via TGF-β and oxidative phosphorylation pathways. 📖 vist.ly/58wxa

🔬 M2 macrophages can boost IL-10–producing B cells, helping reduce inflammation and ease asthma symptoms in mouse models. Highlights a potential new avenue for modulating immune responses in asthma. 📖 vist.ly/58v4w #Immunology #Asthma

📍 We're at #OCION2026 today in Oxford! Stop by the Immunotherapy Advances booth to meet our Journals Manager, Laura Franklin, and chat about publishing your latest immunology and immuno-oncology research. We're actively welcoming submissions! 🧬✨

Discover the benefits available when peer reviewing for the @britsocimm.bsky.social journals, including a chance to work with immunology experts to advance research. 🔗 oxford.ly/4fWq6kZ #ImmunoSky | @ceijournal.bsky.social | @imtadvances.bsky.social | @discovimmunol.bsky.social

🔬 Monocytes play a key role in MS, balancing inflammation and tissue repair. Shifting from pro-inflammatory to repair-associated subsets could offer new therapeutic approaches. 📖 vist.ly/588k5 #Immunology #MultipleSclerosis

🔬 Monocytes play a key role in MS, balancing inflammation and tissue repair. Shifting from pro-inflammatory to repair-associated subsets could offer new therapeutic approaches. 📖 vist.ly/587dc #Immunology #MultipleSclerosis

CAR-T cells lose the temporal regulation of cytokine production seen in TCR-T cells, producing sustained high cytokine levels without external co-stimulation, which may underpin both their potency and toxicity. 🔬 vist.ly/584c5 #Immunology

Phase 3 data show 20% subcutaneous Ig (Ig20Gly) given weekly or every 2 weeks maintains protective IgG levels (>8 g/L) with a favourable safety profile in Japanese patients with PIDs. Flexible dosing with promising clinical impact. vist.ly/57csr #Immunology

Study shows comparable cellular immunogenicity in chronic plaque psoriasis patients receiving continuous Humira® or repeated switching with biosimilar AVT02, supporting interchangeability findings. vist.ly/57a58 #Psoriasis #Biosimilars #Immunology

🔬 Immune sensing vs clearance isn’t always aligned. New work shows loss of neuraminidase A boosts detection of S. pneumoniae but enables intracellular survival, while restoring it improves clearance. Points to NanA as a potential therapeutic target. 📖 vist.ly/573pm

Tracking engineered T cells after infusion is crucial. This study shows a rapid whole-blood assay can assess TCR T cell function in vivo, with cytokine responses reflecting dose in HBV-related liver cancer. 🔗 vist.ly/56rb4 #Immunotherapy #TCells #Immunology

🔬 Regulatory B cells are key to immune balance, but their role in autoimmune disease is highly variable. This highlights the need for more personalised approaches to treatment. 📖 vist.ly/56c84

Submissions still open for the CD40 turns 40 Special Collection, exploring four decades of CD40 biology and its impact on immunotherapy across cancer, autoimmunity, and more 🧬 Submit by end of June 2026. Learn more about submitting here: vist.ly/55mmb #Immunology #Immunotherapy

Population modelling reveals key drivers of CAR T-cell dynamics in lymphoma patients, highlighting roles for lymphodepletion, tumour burden, and cytokines like IL-15/IL-7 🧬 🔗 vist.ly/555yn #Immunotherapy #CARTcells #CancerResearch

A high-affinity ImmTAC® bispecific efficiently redirects T cells to target PRAME+ tumour cells, even at very low antigen levels, highlighting its promise across multiple cancers 🧬 🔗 vist.ly/5422m #Immunotherapy #CancerResearch #Tcells #OpenAccess

A simple whole-blood assay enables rapid, in vivo monitoring of engineered TCR T cell function, capturing cytokine responses post-transfer without complex processing. A practical step for tracking cell therapy performance. 🧬 vist.ly/54bta #Immunotherapy #Tcells #CellTherapy

A step forward in evolving cell therapies for AML: integrating TCR, CAR, BiTE, and safety switch into a single engineered T cell highlights how the field is moving toward multi-functional, adaptable designs to overcome tumor complexity. vist.ly/547pb #Immunotherapy #AML #CellTherapy

📢 New open‑access study shows MAGE‑A4‑specific TCR‑NK cells combine innate NK killing with targeted TCR activity ,offering a potent, safe, “off‑the‑shelf” strategy for solid tumors. 🔗 vist.ly/543q8

Attending the #CIMT2026 Annual Meeting? Visit Booth 9 to meet Laura Franklin and Abbie Joyce and learn more about publishing cancer immunotherapy research in Immunotherapy Advances. Learn more: vist.ly/53znk

Attending #CIMT2026? Immunotherapy Advances is welcoming submissions to its Cancer Vaccines – Global Advances collection (deadline extended to July 2026). Hear more from Guest Editor Prof Lennard Lee, speaking at CIMT today at 14:00. #CancerVaccines #Immunotherapy

📢 New open‑access pediatric PID study published: fSCIG 10% maintains stable IgG levels in children aged 2–<16 years, with consistent pharmacokinetics across age groups and support for every‑3–4‑week dosing, helping reduce treatment burden without compromising efficacy. 🔗 vist.ly/53cur

🫁 #WorldAsthmaDay Open‑access research shows that M2 macrophages help alleviate asthma in mice by promoting IL‑10⁺ B‑cell responses, with evidence pointing to TGF‑β and metabolic pathways as key regulators. Insights into immune regulation in asthma. 👉 vist.ly/537bb #Asthma #Immunology

Marking World Immunization Week 2026 with a call for papers for Cancer Vaccines: Global Advances, highlighting cutting‑edge research in personalised and off‑the‑shelf cancer vaccines. Submissions open until April 2026. 🧬 #WorldImmunizationWeek #CancerVaccines #CallForPapers

🧬 Open‑access study shows how spatial immune architecture and macrophage polarization shape immunotherapy responses in mismatch repair–deficient colorectal cancer, helping explain why metastatic lesions respond differently. 👉 vist.ly/42jfx #Immunotherapy

📢 Last chance to submit! Cancer Vaccines – Global Advances We invite research, reviews, clinical studies, commentaries & TrialsWatch articles on personalised and off‑the‑shelf cancer vaccines. Submit by the end of April 2026 #callforpapers

Can blood‑based T‑cell markers predict PD‑1 therapy response in melanoma? This study suggests yes, highlighting CD8⁺ proliferation in responders and CTLA‑4⁺ Tregs in non‑responders. Read here📄 https://bit.ly/4pw1rVL

📢 Call for submissions: CD40 turns 40 – Four Decades of “Forty”‑fying Immunotherapy We welcome research on CD40/CD154 biology and therapeutic targeting in cancer, autoimmunity, transplantation, allergy & more. ⏰ Submit by June 2026: vist.ly/4zcxi

How Streptococcus pneumoniae interacts with innate immunity matters. New open‑access research shows neuraminidase A (NanA) shapes immune sensing and phagocytic clearance in microglia and macrophages, with implications for pneumococcal meningitis. vist.ly/4y22j

📢 Call for submissions: Cancer Vaccines – Global Advances We invite research, reviews, clinical studies, commentaries & TrialsWatch articles on personalised and off‑the‑shelf cancer vaccines. Submit by the end of April 2026 #callforpapers

Open‑access review explores how targeting monocyte dynamics could offer new therapeutic approaches for multiple sclerosis, with insights from experimental models highlighting monocyte plasticity and inflammation resolution. vist.ly/4ydua

New open‑access paper outlines how the UK Vaccine Innovation Pathway is accelerating cancer vaccine trials across the NHS, boosting recruitment, streamlining delivery, and supporting equitable access. vist.ly/4x25i

New research shows that adding CD28 signalling motifs to the CD3ζ chain boosts IL‑2 production and expansion of TCR‑engineered T cells, without reducing cytotoxicity. A promising step toward stronger TCR therapies for solid tumours. Read here: vist.ly/4wxea #Immunotherapy #TCells

New study shows the Systemic Immune‑Inflammation Index (SIII) is linked to survival in patients on immune checkpoint inhibitors, with lower SIII predicting better outcomes. Read here: vist.ly/4wedi #Immunotherapy #CancerResearch

MAGE‑A4‑specific TCR‑engineered NK cells show strong, safe, off‑the‑shelf potential against solid tumours, combining targeted TCR activity with potent NK cytotoxicity. Learn more: vist.ly/4w8u3 #Immunotherapy #CancerResearch

Discover benefits available when you become a peer reviewer for the @britsocimm.bsky.social journals, including a chance work with immunology experts to advance research. 🔗 oxford.ly/4sz3vPa #ImmunoSky @ceijournal.bsky.social @imtadvances.bsky.social @discovimmunol.bsky.social

New study maps the spatial + immune landscape of metastatic dMMR colorectal cancer, revealing why some lesions respond to immunotherapy while others resist. Macrophage polarization and spatial immune architecture emerge as key drivers of outcome. 🔗 vist.ly/4v6u2

📣 Call for Papers! CD40 turns 40: Four Decades of “Forty”-fying Immunotherapy — is open for submissions until March 2026. Share your work on CD40/CD154 biology, therapeutic targeting, and future immunotherapy innovations. Learn more about submitting here: vist.ly/4us3h

New review by Bouvain et al. highlights how ¹⁹F MRI is transforming immune imaging, offering precise inflammation detection and theranostic potential. Exciting advances include targeted neutrophil manipulation in colitis with improved outcomes. 🔗 vist.ly/4unwr

🔬 New open‑access research shows how T‑cell signals (CD40L & IL‑4) can reduce NK‑cell ADCC against malignant B cells, revealing a resistance mechanism to anti‑CD20 therapy. Combining anti‑CD20 + anti‑NKG2A may overcome it. Read: vist.ly/4tzga

🔬 New open‑access review explores tumour‑associated macrophages (TAMs): their role in tumour progression, metastasis, therapy resistance, and the ongoing challenge of identifying reliable TAM surface markers for immunotherapy development. 🔗 https://bit.ly/4i95qnm

🚨 Call for Papers! “CD40 turns 40: Four Decades of ‘Forty’-fying Immunotherapy.” We invite submissions on CD40/CD154 biology & therapeutic innovation across cancer, autoimmunity, transplantation & allergy. 📝 Deadline: March 2026 📩 More info: [email protected]

🧬 Spatial profiling of metastatic dMMR colorectal cancer shows why some lesions respond to PD‑1 therapy: responsive sites have strong cytotoxic/IFN‑γ activity, while resistant ones show immunosuppressive macrophage programs. 🔗 https://bit.ly/4qSV3bL ##Immunotherapy #CancerResearch

Metabolic dysregulation plays a key role in Behçet’s disease. Elevated glucose & TAG levels drive Th1 differentiation, CD8⁺ T cell activation and B cell antibody production, contributing to immune dysfunction. Read the study: https://bit.ly/44HA2t9

📢 Special Collection CD40 turns 40: Four Decades of ‘Forty’-fying Immunotherapy🧬 Exploring 40 years of CD40/CD154 biology, therapeutics, and future directions across cancer, autoimmunity, transplantation & allergy. Submissions open until March 2026: https://bit.ly/4rMo7lY

New in Immunotherapy Advances: CD137 aptamer–shRNA chimeras show promise for targeting intratumoral Tregs. This approach downregulates key genes like EzH2 & Nrp1 in CD137⁺ Tregs and malignant cells, offering a potential new route for tumour immunotherapy. 🔗 https://bit.ly/4ad5S3o

This #WorldCancerDay, explore how bispecific T‑cell engagers (BiTEs) could strengthen T‑cell responses against solid tumours, and the challenges still holding them back. Read the open access review here: https://bit.ly/4291Ipg #CancerResearch #Immunotherapy #BiTEs

This #WorldCancerDay, explore how boosting natural killer (NK) cell activity, from CAR‑NK therapies to NK‑cell engagers and checkpoint strategies, could strengthen our fight against cancer. Read the open access review: https://bit.ly/4j8dKEW #Immunotherapy #NKcells

🎗️ Ahead of #WorldCancerDay, check out this review by Shania Makker, Charlotte Galley & Clare L Bennett exploring how advances in immunology and mRNA platforms are reshaping the future of therapeutic cancer vaccines. Read the article: https://bit.ly/4cefxGm